Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
C$1.32
+5.6%
C$1.32
C$0.80
C$4.06
C$256.62MN/A1.51 million shs310,601 shs
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
$0.00
$0.00
$0.00
N/AN/A11,650 shs25,300 shs
Almirall, S.A. stock logo
LBTSF
Almirall
$9.51
$9.51
$8.85
$10.18
N/AN/A200 shsN/A
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
$0.00
$0.00
$0.00
$0.00
N/AN/A16.82 million shs49.00 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
0.00%0.00%0.00%0.00%0.00%
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
Almirall, S.A. stock logo
LBTSF
Almirall
0.00%0.00%0.00%+2.37%-1.76%
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
0.00%-14.29%-36.84%-57.14%-81.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/AN/AN/AN/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Almirall, S.A. stock logo
LBTSF
Almirall
N/AN/AN/AN/AN/AN/AN/AN/A
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/A
Almirall, S.A. stock logo
LBTSF
Almirall
N/AN/AN/AN/A
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/AN/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
Almirall, S.A. stock logo
LBTSF
Almirall
N/AN/AN/AN/AN/AN/A
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/AN/A0.00N/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/A-$0.16N/AN/AN/AN/AN/AN/AN/A
Almirall, S.A. stock logo
LBTSF
Almirall
N/A-$0.07N/AN/AN/AN/AN/AN/A
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
N/A-$0.01N/AN/AN/AN/AN/A5/16/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/AN/AN/AN/AN/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/AN/AN/A
Almirall, S.A. stock logo
LBTSF
Almirall
N/AN/AN/AN/AN/A
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
N/AN/AN/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/A
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
32.45%
Almirall, S.A. stock logo
LBTSF
Almirall
16.10%
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
5.62%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
VIVO Cannabis Inc. stock logo
ABCN
VIVO Cannabis
N/A194.41 millionN/ANot Optionable
Abattis Bioceuticals Corp. stock logo
ATTBF
Abattis Bioceuticals
N/AN/AN/ANot Optionable
Almirall, S.A. stock logo
LBTSF
Almirall
1,904N/AN/ANot Optionable
Therapeutic Solutions International, Inc. stock logo
TSOI
Therapeutic Solutions International
3N/AN/ANot Optionable

TSOI, ATTBF, ABCN, ABZA, and LBTSF Headlines

SourceHeadline
ASCO, CAP Call on Manufacturers to Adopt Therapeutic Group LabelingASCO, CAP Call on Manufacturers to Adopt Therapeutic Group Labeling
thenewsmarket.com - April 25 at 2:38 PM
Global Desmoid Tumors Drug Pipeline Research Report 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule TypeGlobal Desmoid Tumors Drug Pipeline Research Report 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type
finance.yahoo.com - April 23 at 12:12 AM
Therapeutic Solutions International IncTherapeutic Solutions International Inc
morningstar.com - April 19 at 9:22 PM
Aion Therapeutic Responds to First-Ever U.S. Drinking Water Standard Making PFAS Removal a Top PriorityAion Therapeutic Responds to First-Ever U.S. Drinking Water Standard Making PFAS Removal a Top Priority
finance.yahoo.com - April 14 at 8:20 PM
Rainbow Therapeutic Riding Center Brightens LivesRainbow Therapeutic Riding Center Brightens Lives
insidenova.com - April 11 at 8:55 AM
Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer VaccineGeneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine
medindia.net - April 8 at 11:50 PM
Therapeutic Vaccine Prevents Pancreatic Cancers Recurrence in 3-Year TrialTherapeutic Vaccine Prevents Pancreatic Cancer's Recurrence in 3-Year Trial
usnews.com - April 8 at 1:46 PM
Therapeutic Solutions International, Inc. (TSOI)Therapeutic Solutions International, Inc. (TSOI)
finance.yahoo.com - April 8 at 8:46 AM
Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple MyelomaKelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma
finance.yahoo.com - April 2 at 6:18 PM
Therapeutic equine program for veterans threatened by property saleTherapeutic equine program for veterans threatened by property sale
theday.com - April 2 at 6:18 PM
Therapeutic mRNA Patent Monitoring Service 2024: Track Competitors IP Activities and their Future IntentionsTherapeutic mRNA Patent Monitoring Service 2024: Track Competitors' IP Activities and their Future Intentions
finance.yahoo.com - April 2 at 6:18 PM
Therapeutic Solutions International files patent for stem cell therapy for degenerative conditionsTherapeutic Solutions International files patent for stem cell therapy for degenerative conditions
pharmaceutical-technology.com - March 26 at 10:05 AM
Aveeno Therapeutic Shave Gel with Oat and Vitamin E to Help Prevent Razor Bumps, Now 24% OffAveeno Therapeutic Shave Gel with Oat and Vitamin E to Help Prevent Razor Bumps, Now 24% Off
msn.com - March 18 at 8:47 PM
Freedom Reins Therapeutic Riding Center Board names program directorFreedom Reins Therapeutic Riding Center Board names program director
duboiscountyherald.com - March 12 at 4:43 AM
Rising Stars Therapeutic Riding Center: Cowgirl Bunco night coming soonRising Stars Therapeutic Riding Center: Cowgirl Bunco night coming soon
msn.com - March 11 at 5:33 PM
Arthritic Therapeutic Market to Reach $ 136.1 billion, Globally, by 2032 at 5.5% CAGR: Allied Market ResearchArthritic Therapeutic Market to Reach $ 136.1 billion, Globally, by 2032 at 5.5% CAGR: Allied Market Research
finance.yahoo.com - March 11 at 5:33 PM
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 PatientsTherapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
finance.yahoo.com - March 4 at 10:45 AM
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell ProductTherapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
finance.yahoo.com - February 29 at 10:07 AM
Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell DifferentiationTherapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell Differentiation
finance.yahoo.com - February 26 at 12:39 PM
Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell DifferentiationTherapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation
businesswire.com - February 26 at 9:00 AM
Therapeutic Intervention Feasible for Preventing Rheumatoid Arthritis in Patients at RiskTherapeutic Intervention Feasible for Preventing Rheumatoid Arthritis in Patients at Risk
physiciansweekly.com - February 26 at 2:00 AM
Therapeutic Solns Intl Stock (OTC:TSOI), Analyst Ratings, Price Targets, PredictionsTherapeutic Solns Intl Stock (OTC:TSOI), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 7:52 AM
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver DiseaseBetter Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
finance.yahoo.com - February 20 at 11:56 AM
Governments plan to drop Therapeutic Products ActGovernment's plan to drop Therapeutic Products Act
sunlive.co.nz - February 19 at 7:34 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

VIVO Cannabis logo

VIVO Cannabis

CVE:ABCN
ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.
Abattis Bioceuticals logo

Abattis Bioceuticals

OTCMKTS:ATTBF
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Almirall logo

Almirall

OTCMKTS:LBTSF
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Therapeutic Solutions International logo

Therapeutic Solutions International

OTCMKTS:TSOI
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. The company also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. In addition, it develops therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology. Therapeutic Solutions International, Inc. was founded in 2007 and is headquartered in Elk City, Idaho.